SILO PHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
SILO PHARMA, INC. (SILO) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 206.60% as of 2025-12-04, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-13
- SILO PHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2021 was 169.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2025-12-04 | 206.60% 10-Q · filed 2026-08-13 | |||
| 2025-09-30 | 259.34% 10-Q · filed 2025-11-13 | |||
| 2025-08-04 | 206.76% 10-Q · filed 2026-08-13 | |||
| 2025-06-30 | 259.34% 10-Q · filed 2025-08-13 | |||
| 2025-05-22 | 259.34% 10-Q · filed 2026-08-13 | |||
| 2021-12-31 | 169.00% 10-K · filed 2022-03-28 | |||
| 2021-09-30 | 169.00% 10-Q · filed 2021-11-10 | |||
| 2019-09-30 | 74.00% 10-Q · filed 2019-11-13 | |||
| 2019-06-30 | 74.00% 10-Q · filed 2019-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |